Literature DB >> 31035184

Gastrointestinal failure affects outcome of intensive care.

Martin Padar1, Joel Starkopf2, Gerli Uusvel3, Annika Reintam Blaser4.   

Abstract

PURPOSE: Goal of this study was to describe incidence and outcome of gastrointestinal failure (GIF) in ICU patients, evaluate its additive role to SOFA score in mortality prediction and describe GIF according to etiology.
MATERIALS AND METHODS: A retrospective study with prospective data collection was conducted in mixed adult ICU patients admitted 2004-2015. GIF was considered present if ≥3 of following 6 symptoms occurred in 1 day: maximum gastric residual volume ≥ 500 mL; absent bowel sounds; vomiting or regurgitation; diarrhea; suspected or radiologically confirmed bowel distension; gastrointestinal bleeding. Division into primary (gastrointestinal pathology causing GIF) and secondary (due to other conditions) GIF was made based on origin of syndrome.
RESULTS: GIF developed in 413 (10.4%) of 3959 patients. Primary GIF occurred in 61.3% and secondary GIF in 38.7% of patients. Development of GIF was associated with longer mechanical ventilation, ICU stay and higher ICU, 30-day and 90-day mortality. Outcomes of patients with primary and secondary GIF were similar. All SOFA sub-scores and number of gastrointestinal symptoms on admission day independently predicted 90-day mortality.
CONCLUSIONS: Gastrointestinal failure, independent of origin, is associated with worse ICU outcome. Similar to other organ failures included in SOFA score, GIF independently predicts mortality.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Critically ill; Gastrointestinal dysfunction; Gastrointestinal failure; Gastrointestinal symptoms; Intensive care

Year:  2019        PMID: 31035184     DOI: 10.1016/j.jcrc.2019.04.001

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  [Monitoring of gastrointestinal dysfunction by near-infrared spectroscopy in children with sepsis: a prospective study].

Authors:  De-Zhen Yao; Li-Jie Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

2.  Comparisons between short-peptide formula and intact-protein formula for early enteral nutrition initiation in patients with acute gastrointestinal injury: a single-center retrospective cohort study.

Authors:  You-Quan Wang; Yan-Hua Li; Yu-Ting Li; Hong-Xiang Li; Dong Zhang
Journal:  Ann Transl Med       Date:  2022-05

3.  Effects of Early Bedside Cycle Exercise on Gastrointestinal Function in Intensive Care Unit Patients Receiving Mechanical Ventilation.

Authors:  Tingting Yu; Fuliang Cai; Rong Jiang
Journal:  Front Med (Lausanne)       Date:  2022-06-09

4.  The Serum Citrulline and D-Lactate are Associated with Gastrointestinal Dysfunction and Failure in Critically Ill Patients.

Authors:  Jin Teng; Lu Xiang; Huaicong Long; Caiping Gao; Lei Lei; Yinghui Zhang
Journal:  Int J Gen Med       Date:  2021-08-03

5.  Gastrointestinal failure score in children with traumatic brain injury.

Authors:  Ying Zhou; Weifeng Lu; Weibing Tang
Journal:  BMC Pediatr       Date:  2021-05-04       Impact factor: 2.125

6.  Gastrointestinal dysfunction during enteral nutrition delivery in intensive care unit (ICU) patients: Risk factors, natural history, and clinical implications. A post-hoc analysis of The Augmented versus Routine approach to Giving Energy Trial (TARGET).

Authors:  Tejaswini Arunachala Murthy; Lee-Anne S Chapple; Kylie Lange; Chinmay S Marathe; Michael Horowitz; Sandra L Peake; Marianne J Chapman
Journal:  Am J Clin Nutr       Date:  2022-08-04       Impact factor: 8.472

7.  "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.

Authors:  Shiv D Kale; Brittney N Mehrkens; Molly M Stegman; Bridget Kastelberg; Henry Carnes; Rachel J McNeill; Amy Rizzo; Saikumar V Karyala; Sheryl Coutermarsh-Ott; Jackie A Fretz; Ying Sun; Jonathan L Koff; Govindarajan Rajagopalan
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.